Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ZFGN

Zafgen (ZFGN) Stock Price, News & Analysis

Zafgen logo

About Zafgen Stock (NASDAQ:ZFGN)

Key Stats

Today's Range
$5.94
$6.60
50-Day Range
$0.99
$25.06
52-Week Range
$0.62
$2.76
Volume
669,472 shs
Average Volume
360,199 shs
Market Capitalization
$227.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Receive ZFGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zafgen and its competitors with MarketBeat's FREE daily newsletter.

ZFGN Stock News Headlines

Tokyo Steel Manufacturing Co Ltd 5423
What Comes Next Could Be a Once-in-a-Lifetime Opportunity
A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.
Food and drink in a castle
LRMR Larimar Therapeutics, Inc.
Form 424B5 Larimar Therapeutics, - StreetInsider.com
See More Headlines

ZFGN Stock Analysis - Frequently Asked Questions

Zafgen Inc (NASDAQ:ZFGN) issued its quarterly earnings data on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, hitting analysts' consensus estimates of ($0.19).

Based on aggregate information from My MarketBeat watchlists, some other companies that Zafgen investors own include Xtrackers California Municipal Bond ETF (CA), Bristol-Myers Squibb (BMY), Endologix (ELGX), Energy Transfer (ET), BlackRock (BLK), TG Therapeutics (TGTX) and SCYNEXIS (SCYX).

Company Calendar

Last Earnings
3/05/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZFGN
Fax
N/A
Employees
38
Year Founded
N/A

Profitability

Net Income
$-45,410,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$227.82 million
Optionable
Not Optionable
Beta
0.27
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ZFGN) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners